论文部分内容阅读
阿德福韦酯于2005年在我国上市,有片剂和胶囊两种剂型,临床上用于治疗有乙型肝炎病毒活动复制证据,并伴有血清氨基酸转移酶(ALT或AST)持续升高或肝脏组织学活动性病变的肝功能代偿的成年慢性乙型肝炎患者。国家药品不良反应监测数据库分析提示,阿德福韦酯在长期使用后可引起低磷血症及骨软化。骨软化主要是非矿化的骨样组织增生,骨质软化,而产生骨痛、骨畸形、骨折等一系列临床症状和体征。
Adefovir dipivoxil listed in China in 2005, tablets and capsules two dosage forms, clinically used to treat hepatitis B virus replication activity evidence, accompanied by continuous increase of serum amino acid transferase (ALT or AST) Or liver function-compensated chronic hepatitis B patients with active liver histology. National ADR monitoring database analysis suggests that adefovir dipivoxil may cause hypophosphatemia and osteomalacia after long-term use. Osteomalacia is mainly non-mineralized bone-like tissue hyperplasia, bone softening, resulting in a series of clinical symptoms and signs of bone pain, bone deformity, fractures.